{
    "hands_on_practices": [
        {
            "introduction": "The initial evaluation of an adrenal mass hinges on characterizing its risk of malignancy, and multiphasic computed tomography (CT) is a primary diagnostic tool. Benign adrenal adenomas are often rich in intracellular lipid, a property that causes them to rapidly release contrast material after initial enhancement. This practice focuses on quantifying this phenomenon through the calculation of absolute washout ($W_{abs}$) and relative washout ($W_{rel}$), which are fundamental skills for interpreting adrenal imaging and distinguishing benign from potentially malignant lesions .",
            "id": "5081283",
            "problem": "A patient with an incidentally discovered adrenal mass undergoes multiphasic Computed Tomography (CT). The attenuation of the lesion in Hounsfield Units (HU) is measured at three time points: unenhanced $HU_{unenh}=8$, early post-contrast $HU_{enh}=90$, and delayed post-contrast $HU_{del}=30$. In adrenal lesion characterization, washout is defined from first principles as the fraction of the initial contrast-related signal that declines between the enhanced and delayed phases. When a true baseline is available (the unenhanced phase), the absolute washout quantifies this fraction relative to the baseline-corrected initial enhancement. When a baseline is not considered, the relative washout quantifies this fraction relative to the enhanced phase alone. Widely accepted benign adenoma criteria state that absolute washout at or above $0.60$ and relative washout at or above $0.40$ are consistent with a lipid-rich adrenal adenoma. Using these principles, compute the absolute washout $W_{abs}$ and relative washout $W_{rel}$ for this lesion, each expressed as a decimal fraction rounded to four significant figures. Then define an indicator $S$ such that $S=1$ if both thresholds ($W_{abs} \\geq 0.60$ and $W_{rel} \\geq 0.40$) are met, and $S=0$ otherwise. Report your final answer as the ordered triple $(W_{abs}, W_{rel}, S)$.",
            "solution": "The problem statement is deemed valid as it is scientifically grounded in the principles of diagnostic radiology, well-posed with sufficient and consistent data, and objectively stated.\n\nThe problem requires the calculation of two diagnostic metrics, absolute washout ($W_{abs}$) and relative washout ($W_{rel}$), for an adrenal lesion based on its attenuation characteristics in a multiphasic Computed Tomography (CT) scan. It also requires the determination of a binary indicator $S$ based on whether these metrics meet established clinical thresholds.\n\nThe given attenuation values in Hounsfield Units (HU) are:\n- Unenhanced phase: $HU_{unenh} = 8$\n- Early post-contrast (enhanced) phase: $HU_{enh} = 90$\n- Delayed post-contrast phase: $HU_{del} = 30$\n\nFirst, we must formalize the definitions of absolute and relative washout based on the provided descriptions.\n\nThe absolute washout, $W_{abs}$, is defined as the fraction of the initial contrast-related signal that declines, relative to the baseline-corrected initial enhancement.\nThe initial enhancement due to contrast is the difference between the enhanced and unenhanced attenuation values. This is the denominator for the absolute washout calculation.\nDenominator for $W_{abs}$: $HU_{enh} - HU_{unenh}$\nThe decline in signal from the enhanced to the delayed phase is the difference between their respective attenuation values. This is the numerator for both washout calculations.\nNumerator for $W_{abs}$ and $W_{rel}$: $HU_{enh} - HU_{del}$\nTherefore, the formula for absolute washout is:\n$$W_{abs} = \\frac{HU_{enh} - HU_{del}}{HU_{enh} - HU_{unenh}}$$\n\nThe relative washout, $W_{rel}$, is defined as the same fraction of decline, but relative to the enhanced phase attenuation value alone, without considering the unenhanced baseline.\nDenominator for $W_{rel}$: $HU_{enh}$\nTherefore, the formula for relative washout is:\n$$W_{rel} = \\frac{HU_{enh} - HU_{del}}{HU_{enh}}$$\n\nNow, we substitute the given numerical values into these formulas.\nFor absolute washout:\n$$W_{abs} = \\frac{90 - 30}{90 - 8} = \\frac{60}{82}$$\nCalculating the decimal value:\n$$W_{abs} \\approx 0.731707317...$$\nRounding to four significant figures as required, we get:\n$$W_{abs} \\approx 0.7317$$\n\nFor relative washout:\n$$W_{rel} = \\frac{90 - 30}{90} = \\frac{60}{90} = \\frac{2}{3}$$\nCalculating the decimal value:\n$$W_{rel} \\approx 0.666666...$$\nRounding to four significant figures as required, we get:\n$$W_{rel} \\approx 0.6667$$\n\nNext, we must determine the value of the indicator $S$. The condition for $S=1$ is that both of the following inequalities are satisfied:\n$1$. $W_{abs} \\geq 0.60$\n$2$. $W_{rel} \\geq 0.40$\nIf either or both of these conditions are not met, then $S=0$.\n\nWe check the conditions using our calculated values:\n$1$. Is $0.7317 \\geq 0.60$? Yes, this is true.\n$2$. Is $0.6667 \\geq 0.40$? Yes, this is true.\n\nSince both conditions are met, the value of the indicator is $S=1$. These results are consistent with the characterization of a benign adrenal adenoma.\n\nThe final answer is the ordered triple $(W_{abs}, W_{rel}, S)$.\n$$(0.7317, 0.6667, 1)$$",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.7317  0.6667  1 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Once malignancy risk is assessed, the next critical step is the hormonal evaluation to determine if the incidentaloma is functional. This exercise delves into the workup for primary aldosteronism, a frequent cause of secondary hypertension. By applying physiological principles of the Renin-Angiotensin-Aldosterone System (RAAS), you will calculate the aldosterone-to-renin ratio (ARR) and articulate why a high ratio in the context of suppressed renin provides powerful evidence of autonomous hormone production, warranting further investigation .",
            "id": "5081334",
            "problem": "A $48$-year-old patient with long-standing, treatment-resistant hypertension and intermittent muscle cramps is found to have a right adrenal mass measuring $2.2\\ \\mathrm{cm}$ on noncontrast Computed Tomography (CT). Pretest standardization is performed: mineralocorticoid receptor antagonists and diuretics are held appropriately, dietary sodium intake is normal, and serum potassium is corrected to normal before morning blood sampling obtained after $15$ minutes seated rest. The laboratory reports a plasma aldosterone concentration of $20\\ \\mathrm{ng/dL}$ and a Plasma Renin Activity (PRA) of $0.2\\ \\mathrm{ng/mL/hr}$.\n\nUsing only fundamental physiology of the Renin-Angiotensin-Aldosterone System (RAAS) and the well-tested clinical practice that screens for autonomous aldosterone secretion in adrenal incidentaloma evaluation by combining plasma aldosterone concentration and PRA into a single index, compute the numerical value of that index from the above measurements. Report the result as a pure number (no units). Then, starting from RAAS principles and the observed measurements, explain why the computed value supports the presence of autonomous aldosterone production and therefore warrants confirmatory testing as part of the systemic surgery evaluation pathway for an adrenal incidentaloma.\n\nDo not round unless necessary; if rounding is needed, round to four significant figures. Express the computed index as a unitless number.",
            "solution": "The problem as stated is scientifically grounded, well-posed, and objective. It provides a classic clinical scenario for the evaluation of primary aldosteronism in the context of an adrenal incidentaloma, with all necessary data for calculation and physiological interpretation. The problem is therefore deemed valid and a solution will be provided.\n\nThe primary task is to compute a screening index from the provided laboratory values and then to explain its significance based on the physiology of the Renin-Angiotensin-Aldosterone System (RAAS).\n\nFirst, we compute the numerical value of the index. This index, commonly known as the Aldosterone-to-Renin Ratio (ARR), is the ratio of the Plasma Aldosterone Concentration (PAC) to the Plasma Renin Activity (PRA).\n\nThe given values are:\n- Plasma Aldosterone Concentration, $\\text{PAC} = 20\\ \\mathrm{ng/dL}$\n- Plasma Renin Activity, $\\text{PRA} = 0.2\\ \\mathrm{ng/mL/hr}$\n\nThe index is calculated by dividing the numerical value of the PAC by the numerical value of the PRA:\n$$ \\text{Index} = \\frac{\\text{PAC}}{\\text{PRA}} $$\nSubstituting the given laboratory values into the formula:\n$$ \\text{Index} = \\frac{20}{0.2} = 100 $$\nAs per the problem's instruction, this is reported as a pure, unitless number, which is the standard clinical convention for this specific ratio, despite the dimensional inconsistency of the input units ($\\mathrm{ng/dL}$ and $\\mathrm{ng/mL/hr}$). The result of the calculation is an exact integer, $100$, so no rounding is necessary.\n\nSecond, we explain why this computed value supports the presence of autonomous aldosterone production. This explanation is rooted in the negative feedback mechanisms that govern the RAAS.\n\n1.  **Normal Physiology of the Renin-Angiotensin-Aldosterone System (RAAS)**: The RAAS plays a central role in regulating blood pressure and extracellular fluid volume. In response to stimuli such as decreased renal perfusion (low blood pressure) or low sodium delivery to the distal nephron, the juxtaglomerular cells of the kidney secrete the enzyme renin. Renin cleaves angiotensinogen to form angiotensin I. Angiotensin I is subsequently converted to angiotensin II by Angiotensin-Converting Enzyme (ACE). Angiotensin II is a potent vasoconstrictor and is the principal physiological stimulus for the synthesis and secretion of aldosterone from the zona glomerulosa of the adrenal cortex. Aldosterone acts on the principal cells of the distal tubule and collecting duct to increase the reabsorption of sodium and water, and to increase the secretion of potassium. This action leads to an expansion of extracellular fluid volume and an increase in blood pressure.\n\n2.  **The Negative Feedback Loop**: A critical feature of the RAAS is its regulation by negative feedback. The end-products of the cascade—increased blood pressure and sodium retention—inhibit the initial signal, leading to the suppression of renin release from the kidneys. Thus, in a state of hypertension and volume expansion, a physiologically normal response is for the body to suppress renin production to very low levels. The subsequent decrease in angiotensin II levels should, in turn, lead to a decrease in aldosterone secretion.\n\n3.  **Application to the Patient's Case**: The patient is described as having long-standing, treatment-resistant hypertension. This chronic hypertensive state should provide a powerful suppressive signal to the RAAS.\n    - We observe that the Plasma Renin Activity ($\\text{PRA}$) is $0.2\\ \\mathrm{ng/mL/hr}$. This value is very low, indicating that the renin secretion is indeed suppressed. This is the expected physiological response of the kidneys to the patient's hypertension and volume-expanded state.\n    - However, the Plasma Aldosterone Concentration ($\\text{PAC}$) is $20\\ \\mathrm{ng/dL}$. This aldosterone level is inappropriately high for a state of renin suppression. With a $\\text{PRA}$ of $0.2\\ \\mathrm{ng/mL/hr}$, the circulating levels of angiotensin II are expected to be minimal, and therefore the primary stimulus for aldosterone secretion is absent. An aldosterone level of $20\\ \\mathrm{ng/dL}$ in this context signifies that its production is uncoupled from its normal regulator, angiotensin II.\n\n4.  **Interpretation and Significance of the Index**: The combination of a low PRA and a non-suppressed PAC is the biochemical signature of autonomous aldosterone production, also known as primary aldosteronism. The adrenal mass, a suspected aldosterone-producing adenoma, is secreting aldosterone independently of the RAAS. This autonomous secretion is the root cause of the patient's clinical presentation: the hypertension is driven by the aldosterone-mediated sodium and water retention, and the muscle cramps are a symptom of the hypokalemia caused by aldosterone-mediated potassium excretion. The calculated index of $100$ quantitatively captures this pathological dysregulation. Clinical guidelines typically use a screening threshold for the index of $\\ge 20$ or $\\ge 30$, often in conjunction with a $\\text{PAC} > 15\\ \\mathrm{ng/dL}$. The patient's index of $100$ is substantially above this threshold, providing strong evidence for primary aldosteronism. This positive screening result justifies proceeding to confirmatory biochemical testing (such as a saline suppression test) to definitively establish the diagnosis before considering surgical removal of the adrenal mass as a definitive treatment.",
            "answer": "$$\\boxed{100}$$"
        },
        {
            "introduction": "The final and most crucial step in managing an adrenal incidentaloma is synthesizing all data to make an evidence-based surgical decision. This capstone practice presents a common and challenging clinical scenario: a mass with benign imaging features (e.g., unenhanced attenuation $10$ Hounsfield Units) that is causing Mild Autonomous Cortisol Secretion (MACS), contributing to metabolic comorbidities like diabetes and hypertension. This case will challenge you to weigh the low oncologic risk against the clear metabolic harm from hormonal excess to determine the definitive indication for surgery .",
            "id": "5081332",
            "problem": "A patient is referred after a non-contrast computed tomography (CT) scan performed for nephrolithiasis detected a unilateral adrenal mass. The lesion measures $3.0$ $\\mathrm{cm}$ in maximum diameter, is homogeneous, and has an unenhanced attenuation of $5$ Hounsfield Units (HU). The patient is asymptomatic from an endocrine perspective but has poorly controlled type $2$ diabetes mellitus despite optimized oral therapy. On endocrine evaluation: the $1$ $\\mathrm{mg}$ overnight dexamethasone suppression test (DST) shows a morning serum cortisol of $70$ $\\mathrm{nmol/L}$, adrenocorticotropic hormone (ACTH) is suppressed, plasma potassium is normal, and there is no history of paroxysmal symptoms suggestive of catecholamine excess. Blood pressure is mildly elevated but not yet on antihypertensive therapy. There are no radiographic features suggestive of local invasion or metastasis.\n\nUsing first principles and core definitions:\n- An adrenal incidentaloma is a clinically inapparent adrenal mass discovered incidentally on imaging performed for non-adrenal indications.\n- On unenhanced CT, a lipid-rich adenoma typically has low attenuation due to intracellular lipid, commonly $10$ HU.\n- The normal hypothalamic–pituitary–adrenal (HPA) axis suppresses adrenal cortisol production in response to dexamethasone; failure to suppress indicates autonomous cortisol secretion. Current consensus defines mild autonomous cortisol secretion when post-DST cortisol $>50$ $\\mathrm{nmol/L}$ (approximately $1.8$ $\\mu\\mathrm{g/dL}$) with low or suppressed ACTH and without overt Cushingoid features.\n\nWhich of the following management plans best aligns with these fundamentals and balances the risks and benefits in this case?\n\nA. Recommend unilateral laparoscopic adrenalectomy after confirming persistent mild autonomous cortisol secretion and excluding other hormone excess as indicated, with perioperative stress-dose glucocorticoids and multidisciplinary team discussion; counsel that surgery may improve glycemic control given the suppressed ACTH and post-DST cortisol of $70$ $\\mathrm{nmol/L}$, despite benign imaging features (HU $=5$ and size $=3.0$ $\\mathrm{cm}$).\n\nB. Defer surgery because the lesion is $4.0$ $\\mathrm{cm}$ and lipid-rich (HU $10$), manage diabetes medically, and discharge from endocrine follow-up as malignancy risk is low and ACTH is suppressed.\n\nC. Proceed to immediate open adrenalectomy due to high suspicion for adrenocortical carcinoma based on the lesion’s size of $3.0$ $\\mathrm{cm}$ and HU of $5$.\n\nD. Initiate lifelong steroidogenesis blockade (for example, ketoconazole) to control hypercortisolism, because surgery is contraindicated in lipid-rich adenomas (HU $10$) and small lesions ($4.0$ $\\mathrm{cm}$).\n\nE. Opt for watchful waiting with annual CT imaging alone, without further hormonal evaluation, because ACTH is suppressed and therefore cortisol excess is clinically insignificant.",
            "solution": "The user has provided a clinical scenario and requested an analysis to determine the most appropriate management plan based on fundamental principles of endocrinology and surgery. I will first validate the problem statement and then proceed to a detailed solution.\n\n### Problem Validation\n\n1.  **Extraction of Givens:**\n    *   **Patient Presentation:** Incidental discovery of a unilateral adrenal mass on a non-contrast computed tomography (CT) scan.\n    *   **Radiographic Findings:**\n        *   Maximum diameter: $3.0$ $\\mathrm{cm}$.\n        *   Morphology: homogeneous.\n        *   Unenhanced attenuation: $5$ Hounsfield Units (HU).\n        *   No features of local invasion or metastasis.\n    *   **Clinical Status:**\n        *   Asymptomatic from an endocrine perspective (i.e., no overt Cushingoid features).\n        *   Poorly controlled type $2$ diabetes mellitus.\n        *   Mildly elevated blood pressure, not on therapy.\n        *   Normal plasma potassium.\n        *   No history of paroxysmal symptoms (ruling out pheochromocytoma clinically).\n    *   **Endocrine Evaluation:**\n        *   $1$ $\\mathrm{mg}$ overnight dexamethasone suppression test (DST) result: morning serum cortisol of $70$ $\\mathrm{nmol/L}$.\n        *   Adrenocorticotropic hormone (ACTH) level: suppressed.\n    *   **Provided Definitions:**\n        *   Adrenal incidentaloma: A clinically inapparent adrenal mass found on imaging for other reasons.\n        *   Lipid-rich adenoma on CT: Unenhanced attenuation $ 10$ HU.\n        *   Mild autonomous cortisol secretion (MACS): Post-DST cortisol $> 50$ $\\mathrm{nmol/L}$ with low/suppressed ACTH, without overt Cushingoid features.\n\n2.  **Validation Analysis:**\n    *   **Scientific Grounding:** The problem is firmly based on established principles of endocrinology and diagnostic radiology. The values for tumor size, HU, and cortisol levels are clinically realistic and standard in medical practice. The definitions provided for adrenal incidentaloma, lipid-rich adenoma, and MACS are consistent with current international consensus guidelines (e.g., from the European Society of Endocrinology). The problem is scientifically sound.\n    *   **Well-Posedness and Objectivity:** The problem presents a clear, self-contained clinical case with sufficient data to arrive at a logical management decision. The question is objective and asks for the best plan based on the provided evidence and principles. A unique, rational answer can be derived.\n    *   **Consistency and Completeness:** The data points are internally consistent. A low HU value ($5$ HU) points to a benign adenoma. A post-DST cortisol of $70$ $\\mathrm{nmol/L}$ with suppressed ACTH confirms autonomous cortisol secretion from this adrenal source. The poorly controlled diabetes and hypertension are known metabolic consequences of such secretion. The problem is complete for the task at hand.\n\n3.  **Verdict:**\n    The problem statement is valid. It is a well-structured, scientifically sound clinical reasoning problem. I will proceed with deriving the solution.\n\n### Derivation of the Correct Management Plan\n\nThe management of an adrenal incidentaloma is guided by two primary considerations: the risk of malignancy and the presence of hormonal hypersecretion.\n\n1.  **Assessment of Malignancy Risk:**\n    *   The size of the lesion is $3.0$ $\\mathrm{cm}$. While size is a predictor of malignancy (risk increases significantly for lesions $> 4.0$ $\\mathrm{cm}$), a size of $3.0$ $\\mathrm{cm}$ is associated with a low risk.\n    *   The imaging phenotype is the most critical feature here. The unenhanced attenuation is $5$ HU. According to the provided definition, an attenuation value less than $10$ HU is highly specific for a benign, lipid-rich adenoma. Adrenocortical carcinomas (ACCs) are typically lipid-poor and thus have a high unenhanced attenuation (usually $> 20$ HU).\n    *   The homogeneity and lack of invasive features further support a benign diagnosis.\n    *   **Conclusion on Malignancy:** The risk of malignancy is extremely low. The lesion is, with high probability, a benign adrenal adenoma. Surgery is not indicated on the basis of cancer risk.\n\n2.  **Assessment of Hormonal Function:**\n    *   The problem states the patient underwent a $1$ $\\mathrm{mg}$ DST, which is the recommended screening test for autonomous cortisol secretion.\n    *   The patient's morning serum cortisol level after dexamethasone was $70$ $\\mathrm{nmol/L}$.\n    *   The provided definition for mild autonomous cortisol secretion (MACS) is a post-DST cortisol $> 50$ $\\mathrm{nmol/L}$. Since $70$ $\\mathrm{nmol/L} > 50$ $\\mathrm{nmol/L}$, the patient meets the biochemical criterion for MACS.\n    *   The finding of a suppressed ACTH level confirms that the cortisol secretion is autonomous (i.e., originating from the adrenal gland itself) and not driven by the pituitary. This completes the diagnosis of MACS.\n    *   **Clinical Significance of MACS:** Although the patient is \"asymptomatic from an endocrine perspective\" (meaning no classic, overt signs of Cushing's syndrome), MACS is strongly associated with adverse metabolic outcomes. The patient's poorly controlled type $2$ diabetes and mild hypertension are very likely consequences of this chronic, low-level cortisol excess. Therefore, the hormonal secretion is clinically significant.\n\n3.  **Synthesis and Management Decision:**\n    *   The patient has a radiologically benign adrenal adenoma ($3.0$ $\\mathrm{cm}$, $5$ HU) that is causing clinically significant mild autonomous cortisol secretion, contributing to metabolic disease (diabetes, hypertension).\n    *   The primary indication for treatment is to resolve the hormonal excess and thereby improve or resolve the associated comorbidities.\n    *   The definitive treatment for a unilateral, functional adrenal adenoma is surgical excision (adrenalectomy). For a benign lesion of this size, a minimally invasive approach (laparoscopic adrenalectomy) is the standard of care.\n    *   Because the adenoma's autonomous production of cortisol has suppressed the patient's entire hypothalamic-pituitary-adrenal (HPA) axis, including the contralateral adrenal gland, abrupt removal of the tumor will lead to a state of adrenal insufficiency. This can be life-threatening if not managed appropriately. Therefore, perioperative administration of stress-dose glucocorticoids is mandatory, followed by a tapering regimen post-operatively until the HPA axis recovers function.\n    *   The decision to operate on a patient with MACS requires careful consideration of surgical risks versus the long-term benefits of ameliorating the metabolic syndrome. This nuanced decision is best made within a multidisciplinary team (MDT).\n    *   Finally, a complete workup for an adrenal mass also includes screening for pheochromocytoma (plasma or urinary metanephrines) and primary aldosteronism (aldosterone-to-renin ratio), especially in the presence of hypertension. Although clinical clues suggest these are negative, formal exclusion is part of a complete management plan.\n\n### Evaluation of Options\n\n**A. Recommend unilateral laparoscopic adrenalectomy after confirming persistent mild autonomous cortisol secretion and excluding other hormone excess as indicated, with perioperative stress-dose glucocorticoids and multidisciplinary team discussion; counsel that surgery may improve glycemic control given the suppressed ACTH and post-DST cortisol of $70$ $\\mathrm{nmol/L}$, despite benign imaging features (HU $=5$ and size $=3.0$ $\\mathrm{cm}$).**\nThis option correctly identifies the core issue: the functional nature of the adenoma and its metabolic consequences. It proposes the correct definitive treatment (laparoscopic adrenalectomy) for the correct reason (to treat MACS and improve comorbidities). It correctly notes the necessity of perioperative stress-dose glucocorticoids, the value of an MDT approach, and the need to complete the hormonal workup. It correctly balances the benign radiographic appearance against the clinically significant hormonal activity.\n**Verdict: Correct**\n\n**B. Defer surgery because the lesion is less than $4.0$ $\\mathrm{cm}$ and lipid-rich (HU $10$), manage diabetes medically, and discharge from endocrine follow-up as malignancy risk is low and ACTH is suppressed.**\nThis option incorrectly prioritizes the low malignancy risk over the confirmed and clinically significant hormonal hypersecretion. Managing the diabetes medically without addressing its underlying adrenal cause is suboptimal. Discharging the patient is inappropriate, as a functional adrenal tumor requires monitoring even if managed non-surgically. The interpretation that suppressed ACTH is a reason for discharge is a dangerous misunderstanding of the pathophysiology.\n**Verdict: Incorrect**\n\n**C. Proceed to immediate open adrenalectomy due to high suspicion for adrenocortical carcinoma based on the lesion’s size of $3.0$ $\\mathrm{cm}$ and HU of $5$.**\nThis option is based on a flawed premise. The radiographic features (size $ 4.0$ $\\mathrm{cm}$ and HU $ 10$) are classic indicators of a *benign* adenoma, not a carcinoma. The suspicion for ACC is very low. Consequently, recommending an open adrenalectomy (which is more morbid than laparoscopic) is also incorrect for a presumed benign lesion of this size.\n**Verdict: Incorrect**\n\n**D. Initiate lifelong steroidogenesis blockade (for example, ketoconazole) to control hypercortisolism, because surgery is contraindicated in lipid-rich adenomas (HU $10$) and small lesions ($4.0$ $\\mathrm{cm}$).**\nThe core premise that surgery is contraindicated is false. Benign features and small size do not contraindicate surgery for a *functional* tumor; on the contrary, they make a curative, minimally invasive surgery an excellent option. Medical therapy is a second-line option for patients who are poor surgical candidates, not the primary treatment for an otherwise healthy individual.\n**Verdict: Incorrect**\n\n**E. Opt for watchful waiting with annual CT imaging alone, without further hormonal evaluation, because ACTH is suppressed and therefore cortisol excess is clinically insignificant.**\nThis option contains multiple errors. It ignores the diagnosed MACS and its impact on the patient's health. It incorrectly suggests forgoing further hormonal evaluation. The reasoning that suppressed ACTH makes the cortisol excess \"clinically insignificant\" is the opposite of the truth; suppressed ACTH is the hallmark of adrenal autonomy and confirms the significance of the adrenal-derived cortisol.\n**Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}